IMM02-KORA not checked
Immunis, Inc. · TRK-820 · MT-9938
FollowEvery change as it happens, and a Monday email
Trials
1 active
1 in total
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “IMM02-KORA (nalfurafine hydrochloride) is a synthetic selective kappa opioid receptor agonist (KORA).”In the company’s words, NCT07905976 on ClinicalTrials.gov
- Main trialPhase 1
- “The goal of this clinical trial is to test Safety and tolerability of single and repeated dose of IMM02-KORA in subjects with PD-associated dyskinesia.”In the company’s words, NCT07905976 on ClinicalTrials.gov
- Other names
- TRK-820 · MT-9938 · AC-820 · KORA
Other drugs for Dyskinesia, Medication-induced
- NBI-1065890Neurocrine Biosciences · Phase 2
- LPM3770164Luye Pharma Group Ltd. · Phase 1/2
- ValbenazineNeurocrine Biosciences · Marketed (Phase 4 trial)
Coming up1
- 30 Dec 2027Phase 1 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Not yet recruiting | 30 Dec 2027 | Safety and Tolerability of Single and Repeated Dose of IMM02-KORA in PD-associated Dyskinesia |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026